Top Markets
#1 MowCat MowCat +803.98%
#2 龙虾 (Lobster) 龙虾 (Lobster) +74.88%
#3 SODAX SODAX +46.96%
#4 Cortex Cortex +28.92%
#5 Magma Finance Magma Finance +18.49%
#6 Akedo Akedo +18.20%
#7 OpenEden OpenEden +17.56%
#8 BNB Attestation Service BNB Attestation Service +13.02%
#9 MANTRA MANTRA +12.47%
#10 APEX APEX +12.10%
Coin of the day
MowCat MowCat
Setări
Limbă
ROMâNă
Monedă
USD
Temă
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Rang în acțiuni #7189
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Preț acțiune
$38.45
Capitalizare de piață
$1.68B
Schimbare (1 zi)
-1.24%
Schimbare (1 an)
50.36%
Țară
KR
Tranzacționează D&D Pharmatech (347850)

Categorie

Healthcare
Istoric dividende pentru D&D Pharmatech (347850)
D&D Pharmatech (simbol acțiune: 347850) a efectuat un total de 0 plăți de dividende.
Suma tuturor dividendelor (ajustată pentru split-uri de acțiuni) este: 0.00
Randamentul dividendului (TTM): 0
Plăți de dividende pentru D&D Pharmatech (347850) din 2026 până în 2026
Plăți anuale de dividende
An Dividend (ajustat pentru split de acțiuni) Schimbă
Nu sunt suficiente date pentru perioada selectată.
Lista tuturor plăților de dividende
An Dividend Schimbă
Nu sunt suficiente date pentru perioada selectată.
Dividende ale companiilor similare sau concurente
Companie Număr de plăți de dividende Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH